

WHAT IS CLAIMED IS:

1. A human interleukin-3 mutant polypeptide

Formula I:

5 Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1 5 10 15
 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30
10 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
15 50 55 60
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75
20 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 80 85 90
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 95 100 105
25 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 110 115 120
 Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID
30 125 130

NO:15)

35 wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or
 Arg;
 Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
 Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;

- Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn,
Thr, Ser or
Val;
5 Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln,
Leu, Val or
Gly;
Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe,
Leu, Ser, or Arg;
10 Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
15 Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or
Lys;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
20 Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg,
Ala, Phe,
Ile or Met;
Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
25 Xaa at position 36 is Asp, Leu, or Val;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn, or Ala;
Xaa at position 40 is Leu, Trp, or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;
30 Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val,
Glu, Phe,
Tyr, Ile, Met or Ala;
Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln,
Arg, Thr,
35 Gly or Ser;
Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu,
Asn, Gln,

Ala or Pro;

Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn,

Arg, Ser, Ala, Ile, Glu or His;

5 Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala,

Tyr, Ile, Val or Gly;

Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys,

10 Thr, Ala,

Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val,

15 His, Phe, Met or Gln;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

20 Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys;

25 Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;

Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

30 Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, Asp, or Ile;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

35 Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;

- Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;
- Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;
- Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;
- Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
- Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
- Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;
- Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;
- Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
- Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;
- Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;
- Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;
- Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;
- Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;
- Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;
- Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;
- Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;
- Xaa at position 85 is Leu, Asn, Val, or Gln;
- Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;
- Xaa at position 87 is Leu, Ser, Trp, or Gly;
- Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;
- Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;
- Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;
- Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;
- Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;
- Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;
- Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;
- Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser,

Ala, Trp, Phe, Ile, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;

5 Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr,

Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln,

Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln,

10 or Pro;

Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,

Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

15 Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,

Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,

Leu, Lys, Ile, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;

20 Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser,

Ala or

Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu,

25 Ser, Ala,

or Trp;

Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

30 Lys, Leu, Ile, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,

35 Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
 Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;
 Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or
 Gly;

5 Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,
 Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

10 and which can additionally have Met- preceding the amino acid in
 position 1; and wherein from 1 to 14 amino acids can be deleted
 from the N-terminus and/or from 1 to 15 amino acids can be deleted
 from the C-terminus; and wherein from 4 to 44 of the amino acids
 designated by Xaa are different from the corresponding amino acids
 of native (1-133) human interleukin-3.

15

2. A human interleukin-3 mutant polypeptide of the
 Formula II:

20 Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa
 20 25 30

25 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa
 35 40 45

Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa
 30 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75

35 Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa
 80 85 90

Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

95 100

105

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa

5

110 115

120

Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:16]

125 130

wherein

- 10 Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 20 is Ile or Pro;
Xaa at position 21 is Asp or Glu;
- 15 Xaa at position 23 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Phe, Gly, Arg, or Ala;
Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, or Val;
- 20 Xaa at position 29 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, or Glu;
- 25 Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu,
Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp or Leu;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
- 30 Xaa at position 38 is Asn or Ala;
Xaa at position 41 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met,
Tyr, Val or Arg;
Xaa at position 44 is Asp or Glu;
- 35 Xaa at position 45 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn, Glu,
Ser, or Trp;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu,

His, Lys, Tyr, Val or Gly;

Xaa at position 47 is Ile, Val, or His;

Xaa at position 49 is Met, Asn, or Asp;

Xaa at position 50 is Glu, Thr, Ala, Asn, Ser or Asp;

5 Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn or Gly;

Xaa at position 53 is Leu, Met, or Phe;

Xaa at position 54 is Arg, Ala, or Ser;

Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

10 Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu,
His, Leu,

Thr, Val or Lys;

Xaa at position 59 is Glu, Tyr, His, Leu, or Arg;

Xaa at position 60 is Ala, Ser, Asn, or Thr;

15 Xaa at position 61 is Phe or Ser;

Xaa at position 62 is Asn, Val, Pro, Thr, or Ile;

Xaa at position 63 is Arg, Tyr, Lys, Ser, His, or Val;

Xaa at position 64 is Ala or Asn;

Xaa at position 65 is Val, Thr, Leu, or Ser;

20 Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Phe, Val, Gly, Asn, Ile, or His;

Xaa at position 68 is Leu, Val, Ile, Phe, or His;

Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 70 is Asn or Pro;

25 Xaa at position 71 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or

Pro;

Xaa at position 74 is Ile or Met;

30 Xaa at position 75 is Glu, Gly, Asp, Ser, or Gln;

Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or

Asp;

Xaa at position 77 is Ile, Ser, or Leu;

Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or

35 Asp;

Xaa at position 80 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, or Val;

- Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His,
Met, Phe, Ser, Thr, Tyr or Val;
- Xaa at position 83 is Pro, Ala, Thr, Trp, or Met;
- Xaa at position 85 is Leu or Val;
- 5 Xaa at position 87 is Leu or Ser;
- Xaa at position 88 is Ala, Arg, or Trp;
- Xaa at position 89 is Thr, Asp, Glu, His, Asn, or Ser;
- Xaa at position 90 is Ala, Asp, or Met;
- Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
- 10 Xaa at position 92 is Pro or Ser;
- Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
- Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe,
Ser or Thr;
- Xaa at position 96 is Pro or Tyr;
- 15 Xaa at position 97 is Ile, Val, or Ala;
- Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Leu, Arg,
Gln, Glu,
Lys, Met, Ser, Tyr, Val or Pro;
- Xaa at position 99 is Ile, Leu, Val, or Phe;
- 20 Xaa at position 100 is Lys, Leu, His, Arg, Ile, Gln, Pro, or
Ser;
- Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,
Asn, Ile, Leu or Tyr;
- Xaa at position 102 is Gly, Glu, Lys, or Ser;
- 25 Xaa at position 104 is Trp, Val, Tyr, Met, or Leu;
- Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,
Leu, Lys, Ile, Asp, or His;
- Xaa at position 106 is Glu, Ser, Ala, or Gly;
- Xaa at position 108 is Arg, Ala, Gln, Ser or Lys;
- 30 Xaa at position 109 is Arg, Thr, Glu, Leu, Ser, or Gly;
- Xaa at position 112 is Thr, Val, Gln, Glu, His, or Ser;
- Xaa at position 114 is Tyr or Trp;
- Xaa at position 115 is Leu or Ala;
- Xaa at position 116 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn,
Gln, His, Met, Phe, Tyr or Ile;
- 35 Xaa at position 117 is Thr, Ser, or Asn;
- Xaa at position 119 is Glu, Ser, Pro, Leu, Thr, or Tyr;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or
Gly;

5 Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,
Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

10 and which can additionally have Met- preceding the amino acid in
position 1; and wherein from 1 to 14 amino acids can be deleted
from the N-terminus and/or from 1 to 15 amino acids can be deleted
from the C-terminus; and wherein from 4 to 44 of the amino acids
designated by Xaa are different from the corresponding amino acids
of native (1-133) human interleukin-3.

15 3. A human interleukin-3 mutant polypeptide according
to claim 2 of the Formula III:

| | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Ala | Pro | Met | Thr | Gln | Thr | Thr | Ser | Leu | Lys | Thr | Ser | Trp | Val | Asn |
| | 1 | | | 5 | 10 | | | | | 15 | | | | | |
| 20 | Cys | Xaa | Xaa | Xaa | Ile | Xaa | Glu | Xaa | Xaa | Xaa | Xaa | Leu | Lys | Xaa | Xaa |
| | | | | 20 | 25 | | | | | 30 | | | | | |
| | Xaa | Xaa | Xaa | Xaa | Xaa | Asp | Xaa | Xaa | Asn | Leu | Asn | Xaa | Glu | Xaa | Xaa |
| 25 | | | | 35 | 40 | | | | | 45 | | | | | |
| | Xaa | Ile | Leu | Met | Xaa | Xaa | Asn | Leu | Xaa | Xaa | Xaa | Asn | Leu | Glu | Xaa |
| | | | | 50 | 55 | | | | | 60 | | | | | |
| 30 | Phe | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Asn | Xaa | Xaa | Xaa | Ile | Glu |
| | | | | 65 | 70 | | | | | 75 | | | | | |
| | Xaa | Xaa | Leu | Xaa | Xaa | Leu | Xaa | Xaa | Cys | Xaa | Pro | Xaa | Xaa | Thr | Ala |
| | | | | 80 | 85 | | | | | 90 | | | | | |
| 35 | Xaa | Pro | Xaa | Arg | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Gly | Asp | Xaa | Xaa |
| | | | | 95 | 100 | | | | | 105 | | | | | |

Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa
110 115 120

5 Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:17]
125 130

wherein

- 10 Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 19 is Met or Ile;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, or Leu;
15 Xaa at position 25 is Thr, His, Gln, or Ala;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln, Asn, or Val;
Xaa at position 30 is Pro, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, or Gln;
20 Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln,
Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
25 Xaa at position 37 is Phe, Ser, Pro, or Trp;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu,
Met, Tyr or Arg;
Xaa at position 44 is Asp or Glu;
30 Xaa at position 45 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu,
Ser or Lys;
Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn Gln, Glu, His,
Ile, Lys, Tyr, Val or Cys;
Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;
35 Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 54 is Arg or Ala;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;

- Xaa at position 56 is Pro, Gly, Ser, Gln, Ala, Asn, Glu,
Leu, Thr, Val or Lys;
- Xaa at position 60 is Ala or Ser;
- Xaa at position 62 is Asn, Pro, Thr, or Ile;
- 5 Xaa at position 63 is Arg or Lys;
- Xaa at position 64 is Ala or Asn;
- Xaa at position 65 is Val or Thr;
- Xaa at position 66 is Lys or Arg;
- Xaa at position 67 is Ser, Phe, or His;
- 10 Xaa at position 68 is Leu, Ile, Phe, or His;
- Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
- Xaa at position 71 is Ala, Pro, or Arg;
- Xaa at position 72 is Ser, Glu, Arg, or Asp;
- Xaa at position 73 is Ala or Leu;
- 15 Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
- Xaa at position 77 is Ile or Leu;
- Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or
Asp;
- Xaa at position 80 is Asn, Gly, Glu, or Arg;
- 20 Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His,
Ile, Met, Phe, Ser, Thr, Tyr or Val;
- Xaa at position 83 is Pro or Thr;
- Xaa at position 85 is Leu or Val;
- Xaa at position 87 is Leu or Ser;
- 25 Xaa at position 88 is Ala or Trp;
- Xaa at position 91 is Ala or Pro;
- Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
- Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser
or Thr;
- 30 Xaa at position 96 is Pro or Tyr;
- Xaa at position 97 is Ile or Val;
- Xaa at position 98 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln,
Leu, Lys, Met, Ser, Tyr, Val or Pro;
- Xaa at position 99 is Ile, Leu, or Val;
- 35 Xaa at position 100 is Lys, Arg, Ile, Gln, Pro, or Ser;
- Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn,
Ile, Leu or Tyr;

Xaa at position 104 is Trp or Leu;

Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu,
Lys, Ile, Asp, or His;

Xaa at position 106 is Glu or Gly;

5 Xaa at position 108 is Arg, Ala, or Ser;

Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;

Xaa at position 112 is Thr, Val, or Gln;

Xaa at position 114 is Tyr or Trp;

Xaa at position 115 is Leu or Ala;

10 Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met,
Phe, Tyr or Ile;

Xaa at position 117 is Thr or Ser;

Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;

Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;

15 Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,
Ile, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

20 and which can additionally have Met- preceding the amino acid in
position 1; and wherein from 1 to 14 amino acids can be deleted
from the N-terminus and/or from 1 to 15 amino acids can be deleted
from the C-terminus; and wherein from 4 to 35 of the amino acids
designated by Xaa are different from the corresponding amino acids
of native (1-133)human interleukin-3.

25

4. A human interleukin-3 mutant polypeptide according
to Claim 3 of the Formula IV:

| | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Ala | Pro | Met | Thr | Gln | Thr | Thr | Ser | Leu | Lys | Thr | Ser | Trp | Val | Asn |
| 30 | 1 | | | 5 | 10 | | | | | 15 | | | | | |
| | Cys | Xaa | Xaa | Met | Ile | Asp | Glu | Xaa | Ile | Xaa | Xaa | Leu | Lys | Xaa | Xaa |
| | | | | 20 | 25 | | | | | 30 | | | | | |
| 35 | Pro | Xaa | Pro | Xaa | Xaa | Asp | Phe | Xaa | Asn | Leu | Asn | Xaa | Glu | Asp | Xaa |
| | | | | 35 | 40 | | | | | 45 | | | | | |

Xaa Ile Leu Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala
 50 55 60

Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu
 5 65 70 75

Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala
 80 85 90

10 Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa
 95 100 105

Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa
 110 115 120

15 Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe [SEQ ID NO:18]
 125 130

wherein

Xaa at position 17 is Ser, Gly, Asp, or Gln;

20 Xaa at position 18 is Asn, His, or Ile;

Xaa at position 23 is Ile, Ala, Leu, or Gly;

Xaa at position 25 is Thr, His, or Gln;

Xaa at position 26 is His or Ala;

Xaa at position 29 is Gln or Asn;

25 Xaa at position 30 is Pro or Gly;

Xaa at position 32 is Leu, Arg, Asn, or Ala;

Xaa at position 34 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile,
 Phe, Thr, or Met;

Xaa at position 35 is Leu, Ala, Asn, or Pro;

30 Xaa at position 38 is Asn or Ala;

Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met,
 Tyr or Arg;

Xaa at position 45 is Gln, Val, Met, Leu, Ala, Asn, Glu, or Lys;

Xaa at position 46 is Asp, Phe, Ser, Gln, Glu, His, Val
 35 or Thr;

Xaa at position 50 is Glu Asn, Ser or Asp;

Xaa at position 51 is Asn, Arg, Pro, Thr, or His;

- Xaa at position 55 is Arg, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 62 is Asn, Pro, or Thr;
Xaa at position 64 is Ala or Asn;
5 Xaa at position 65 is Val or Thr;
Xaa at position 67 is Ser or Phe;
Xaa at position 68 is Leu or Phe;
Xaa at position 69 is Gln, Ala, Glu, or Arg;
Xaa at position 76 is Ser, Val, Asn, Pro, or Gly;
10 Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Gly, Asn, Met, Arg, Ile, or Gly;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met,
Phe, Ser, Thr, Tyr or Val;
15 Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, or Ala;
Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
20 Xaa at position 98 is His, Ile, Asn, Ala, Thr, Gln, Glu,
Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 99 is Ile or Leu;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, Ile,
25 Leu or Tyr;
Xaa at position 105 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr or Gln;
30 Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 122 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
35 Xaa at position 123 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- preceding the amino acid in

position 1; wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from 4 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3.

5. The human interleukin-3 mutant polypeptide of claim 1 wherein 1-15 amino acids are deleted from the C-terminus and/or 1-14 amino acids are deleted from the N-terminus.

6. The human interleukin-3 mutant polypeptide of claim 1 wherein;

Xaa at position 42 is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala;
 Xaa at position 45 is Gln, Val, Met or Asn;
 Xaa at position 46 is Asp, Ser, Gln, His or Val;
 Xaa at position 50 is Glu or Asp;
 Xaa at position 51 is Asn, Pro or Thr;
 Xaa at position 62 is Asn or Pro;
 Xaa at position 76 is Ser, or Pro;
 Xaa at position 82 is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr;
 Xaa at position 95 is His, Arg, Thr, Asn or Ser;
 Xaa at position 98 is His, Ile, Leu, Ala, Gln, Lys, Met, Ser, Tyr or Val;
 Xaa at position 100 is Lys or Arg;
 Xaa at position 101 is Asp, Pro, His, Asn, Ile or Leu;
 Xaa at position 105 is Asn, or Pro;
 Xaa at position 108 is Arg, Ala, or Ser;
 Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, or Tyr;
 Xaa at position 121 is Ala, or Ile;
 Xaa at position 122 is Gln, or Ile; and
 Xaa at position 123 is Ala, Met or Glu.

7. A (15-125)human interleukin-3 mutant polypeptide of the Formula V:

Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

10

15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa
 20 25 30

5

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45

10

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75

15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 80 85 90

Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 95 100 105

20

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:19]
 110

wherein

25

Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;
 Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
 Xaa at position 5 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
 Xaa at position 6 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
 Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn,

30

Thr, Ser or Val;
 Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln,
 Leu, Val, or Gly;
 Xaa at position 9 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe,
 Leu, Ser, or Arg;

35

Xaa at position 10 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
 Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
 Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

- Xaa at position 13 is Leu, Gly, Arg, Thr, Ser, Ala;
- Xaa at position 14 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
- Xaa at position 15 is Gln, Asn, Leu, Pro, Arg, or Val;
- Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or
- 5 Lys;
- Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
- Xaa at position 18 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
- Xaa at position 19 is Pro, Leu, Gln, Ala, Thr, or Glu;
- Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr,
- 10 Arg, Ala, Phe, Ile or Met;
- Xaa at position 21 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
- Xaa at position 22 is Asp, Leu, or Val;
- Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
- Xaa at position 24 is Asn, or Ala;
- 15 Xaa at position 26 is Leu, Trp, or Arg;
- Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met, Pro;
- Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu,
- Val, Glu, Phe, Tyr, Ile or Met;
- Xaa at position 29 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln,
- 20 Arg, Thr, Gly or Ser;
- Xaa at position 30 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu,
- Asn, Gln, Ala or Pro;
- Xaa at position 31 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp,
- Asn, Arg, Ser, Ala, Ile, Glu, His or Trp;
- 25 Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln,
- Lys, His, Ala, Tyr, Ile, Val or Gly;
- Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro, or His;
- Xaa at position 34 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu,
- Lys, Thr, Ala, Met, Val or Asn;
- 30 Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
- Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala,
- Ile, Val, His, Phe, Met or Gln;
- Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
- Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
- 35 Xaa at position 39 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser,
- Met, or;
- Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn,

Lys, His, Ala or Leu;

Xaa at position 41 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys;

- 5 Xaa at position 43 is Asn or Gly;
 Xaa at position 44 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
 Xaa at position 45 is Glu Tyr, His, Leu, Pro, or Arg;
 Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn, or Thr;
 Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
- 10 Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;
 Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
 Xaa at position 50 is Ala, Asn, Pro, Ser, or Lys;
 Xaa at position 51 is Val, Thr, Pro, His, Leu, Phe, or Ser;
 Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
- 15 Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
 Xaa at position 54 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;
 Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;
- 20 Xaa at position 56 is Asn, Leu, Val, Trp, Pro, or Ala;
 Xaa at position 57 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;
 Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
 Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
- 25 Xaa at position 60 is Ile, Met, Thr, Pro, Arg, Gly, Ala;
 Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;
 Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
- 30 Xaa at position 63 is Ile, Ser, Arg, Thr, or Leu;
 Xaa at position 64 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;
 Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
- Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;
- 35 Xaa at position 67 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;
 Xaa at position 68 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;

- Xaa at position 69 is Pro, Ala, Thr, Trp, Arg, Met;
- Xaa at position 70 is Cys, Glu, Gly, Arg, Met, or Val;
- Xaa at position 71 is Leu, Asn, Val, or Gln;
- Xaa at position 72 is Pro, Cys, Arg, Ala, or Lys;
- 5 Xaa at position 73 is Leu, Ser, Trp, or Gly;
- Xaa at position 74 is Ala, Lys, Arg, Val, or Trp;
- Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;
- Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;
- 10 Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;
- Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;
- Xaa at position 79 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;
- Xaa at position 80 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro;
- 15 Xaa at position 81 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile or Tyr;
- Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile, or Thr;
- Xaa at position 83 is Ile, Val, Lys, Ala, or Asn;
- 20 Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
- Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;
- Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, Pro;
- 25 Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu or Gln;
- Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
- Xaa at position 89 is Asp, or Ser;
- 30 Xaa at position 90 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;
- Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
- Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
- 35 Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro;
- Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 96 is Lys, Asn, Thr, Leu, Gln, ...

His, Glu, Ser, Ala or Trp;

Xaa at position 97 is Leu, Ile, Arg, Asp, or Met;

Xaa at position 98 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;

5 Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

Lys, Leu, Ile, Val or Asn;

Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 101 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met;

10 Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg,
Trp, Ser,

Asn, His, Ala, Tyr, Phe, Gln, or Ile;

Xaa at position 103 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;

Xaa at position 104 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

15 Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 106 is Asn, Ala, Pro, Leu, His, Val, or Gln;

Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or

Gly;

Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,

20 Ile, Tyr, or Cys;

Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 44 of the amino

25 acids designated by Xaa are different from the corresponding native amino acids of (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

30 8. A (15-125)human interleukin-3 mutant polypeptide of
the Formula VI:

Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa

1

5

10

15

35

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa

20 25

30

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa
 35 40 45

5 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60

Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa
 65 70 75

10 Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
 80 85 90

Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa
 15 95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:20]
 110

20 wherein
 Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
 Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
 Xaa at position 5 is Met, Phe, Ile, Arg, or Ala;
 Xaa at position 6 is Ile or Pro;

25 Xaa at position 7 is Asp, or Glu;
 Xaa at position 9 is Ile, Val, Ala, Leu, or Gly;
 Xaa at position 10 is Ile, Val, Phe, or Leu;
 Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
 Xaa at position 12 is His, Phe, Gly, Arg, or Ala;

30 Xaa at position 14 is Lys, Leu, Gln, Gly, Pro, or Val;
 Xaa at position 15 is Gln, Asn, Leu, Arg, or Val;
 Xaa at position 16 is Pro, His, Thr, Gly, or Gln;
 Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
 Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;

35 Xaa at position 19 is Pro, Leu, Gln, Ala, or Glu;
 Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln,
 Glu, Ile, Phe, Thr or Met;

- Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, Val;
- Xaa at position 22 is Asp or Leu;
- Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
- Xaa at position 24 is Asn or Ala;
- 5 Xaa at position 27 is Asn, Cys, Arg, His, Met, or Pro;
- Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg;
- Xaa at position 30 is Asp, or Glu;
- Xaa at position 31 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn Glu, Ser or Trp;
- 10 Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;
- Xaa at position 33 is Ile, Val, or His;
- Xaa at position 35 is Met, Asn, or Asp;
- 15 Xaa at position 36 is Glu, Thr, Ala, Asn, Ser or Asp;
- Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
- Xaa at position 38 is Asn or Gly;
- Xaa at position 39 is Leu, Met, or Phe;
- Xaa at position 40 is Arg, Ala or Ser;
- 20 Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
- Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;
- Xaa at position 45 is Glu, Tyr, His, Leu, or Arg;
- Xaa at position 46 is Ala, Ser, Asn, or Thr;
- 25 Xaa at position 47 is Phe or Ser;
- Xaa at position 48 is Asn, Val, Pro, Thr, or Ile;
- Xaa at position 49 is Arg, Tyr, Lys, Ser, His, or Val;
- Xaa at position 50 is Ala or Asn;
- Xaa at position 51 is Val, Thr, Leu, or Ser;
- 30 Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
- Xaa at position 53 is Ser, Phe, Val, Gly, Asn, Ile, or His;
- Xaa at position 54 is Leu, Val, Ile, Phe, or His;
- Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
- Xaa at position 56 is Asn or Pro;
- 35 Xaa at position 57 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;
- Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
- Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or

Pro;

- Xaa at position 60 is Ile or Met;
- Xaa at position 61 is Glu, Gly, Asp, Ser, or Gln;
- Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or
- 5 Asp;
- Xaa at position 63 is Ile, Ser, or Leu;
- Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or
- Asp;
- Xaa at position 66 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
- 10 Xaa at position 67 is Leu, or Val;
- Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu,
- His, Met, Phe, Ser, Thr, Tyr or Val;
- Xaa at position 69 is Pro, Ala, Thr, Trp, or Met;
- Xaa at position 71 is Leu or Val;
- 15 Xaa at position 73 is Leu or Ser;
- Xaa at position 74 is Ala, Arg, or Trp;
- Xaa at position 75 is Thr, Asp, Glu, His, Asn, or Ser;
- Xaa at position 76 is Ala, Asp, or Met;
- Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
- 20 Xaa at position 78 is Pro or Ser;
- Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
- Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe,
- Ser or Thr;
- Xaa at position 82 is Pro or Tyr;
- 25 Xaa at position 83 is Ile, Val, or Ala;
- Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr,
- Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Pro;
- Xaa at position 85 is Ile, Leu, Val, or Phe;
- Xaa at position 86 is Lys, Leu, His, Arg, Ile, Gln, Pro or
- 30 Ser;
- Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val,
- Asn, Ile, Leu or Tyr;
- Xaa at position 88 is Gly, Glu, Lys, or Ser;
- Xaa at position 90 is Trp, Val, Tyr, Met, or Leu;
- 35 Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr,
- Leu, Lys, Ile, Asp, or His;
- Xaa at position 92 is Glu, Ser, Ala, or Gly;

- Xaa at position 94 is Arg, Ala, Gln, Ser or Lys;
 Xaa at position 95 is Arg, Thr, Glu, Leu, Ser, or Gly;
 Xaa at position 98 is Thr, Val, Gln, Glu, His, or Ser;
 Xaa at position 100 is Tyr or Trp;
 5 Xaa at position 101 is Leu or Ala;
 Xaa at position 102 is Lys, Thr, Met, Val, Trp, Ser, Leu,
 Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;
 Xaa at position 103 is Thr, Ser, or Asn;
 Xaa at position 105 is Glu, Ser, Pro, Leu, Thr, or Tyr;
 10 Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
 Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or
 Gly;
 Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,
 Ile, Tyr, or Cys;
 15 Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
- and which can additionally have Met- or Met-Ala- preceding the
 amino acid in position 1; and wherein from 4 to 44 of the amino
 acids designated by Xaa are different from the corresponding amino
 20 acids of native (1-133) human interleukin-3; or a polypeptide
 having substantially the same structure and substantially the same
 biological activity.

9. A (15-125)human interleukin-3 mutant polypeptide
 25 according to Claim 7 of the Formula VII:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Cys | Xaa | Xaa | Xaa | Ile | Xaa | Glu | Xaa | Xaa | Xaa | Xaa | Leu | Lys | Xaa | |
| 1 | | | 5 | 10 | | | | | 15 | | | | | | |
| 30 | Xaa | Xaa | Xaa | Xaa | Xaa | Asp | Xaa | Xaa | Asn | Leu | Asn | Xaa | Glu | Xaa | |
| | | | 20 | 25 | | | | | 30 | | | | | | |
| | Xaa | Xaa | Ile | Leu | Met | Xaa | Xaa | Asn | Leu | Xaa | Xaa | Xaa | Asn | Leu | Glu |
| | | | 35 | 40 | | | | | 45 | | | | | | |
| 35 | Xaa | Phe | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Asn | Xaa | Xaa | Xaa | Ile |
| | | | 50 | 55 | | | | | 60 | | | | | | |

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr
 65 70 75

5 Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa
 80 85 90

10 Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu
 95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:21]
 110

- 15 wherein
 Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
 Xaa at position 4 is Asn, His, or Ile;
 Xaa at position 5 is Met or Ile;
 Xaa at position 7 is Asp or Glu;
- 20 Xaa at position 9 is Ile, Ala, Leu, or Gly;
 Xaa at position 10 is Ile, Val, or Leu;
 Xaa at position 11 is Thr, His, Gln, or Ala;
 Xaa at position 12 is His or Ala;
 Xaa at position 15 is Gln, Asn, or Val;
- 25 Xaa at position 16 is Pro, Gly, or Gln;
 Xaa at position 17 is Pro, Asp, Gly, or Gln;
 Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
 Xaa at position 19 is Pro or Glu;
 Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg,
- 30 Gln, Glu, Ile, Phe, Thr or Met;
 Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
 Xaa at position 23 is Phe, Ser, Pro, or Trp;
 Xaa at position 24 is Asn or Ala;
 Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile,
- 35 Leu, Met Tyr or Arg;
 Xaa at position 30 is Asp or Glu;
 Xaa at position 31 is Gln, Val, Met, Leu, Thr, Ala, Asn,

Glu, Ser or Lys;

Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gln, Glu,
His, Ile, Lys, Tyr, Val or Cys;

Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;

5 Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 40 is Arg or Ala;

Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;

Xaa at position 42 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu,
Thr, Val or Lys;

10 Xaa at position 46 is Ala or Ser;

Xaa at position 48 is Asn, Pro, Thr, or Ile;

Xaa at position 49 is Arg or Lys;

Xaa at position 50 is Ala or Asn;

Xaa at position 51 is Val or Thr;

15 Xaa at position 52 is Lys or Arg;

Xaa at position 53 is Ser, Phe, or His;

Xaa at position 54 is Leu, Ile, Phe, or His;

Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;

Xaa at position 57 is Ala, Pro, or Arg;

20 Xaa at position 58 is Ser, Glu, Arg, or Asp;

Xaa at position 59 is Ala or Leu;

Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;

Xaa at position 63 is Ile or Leu;

Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or

25 Asp;

Xaa at position 66 is Asn, Gly, Glu, or Arg;

Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu,
His, Ile, Met, Phe, Ser, Thr, Tyr or Val;

Xaa at position 69 is Pro or Thr;

30 Xaa at position 71 is Leu or Val;

Xaa at position 73 is Leu or Ser;

Xaa at position 74 is Ala or Trp;

Xaa at position 77 is Ala or Pro;

Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;

35 Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe,
Ser or Thr;

Xaa at position 82 is Pro or Tyr;

- Xaa at position 83 is Ile or Val;
 Xaa at position 84 is His, Ile, Asn, Leu, Ala, Thr, Leu, Arg,
 Gln, Leu, Lys, Met, Ser, Tyr, Val or Pro;
 Xaa at position 85 is Ile, Leu, or Val;
 5 Xaa at position 86 is Lys, Arg, Ile, Gln, Pro, or Ser;
 Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, Ile,
 Leu or Tyr;
 Xaa at position 90 is Trp or Leu;
 Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu,
 10 Lys, Ile, Asp, or His;
 Xaa at position 92 is Glu, or Gly;
 Xaa at position 94 is Arg, Ala, or Ser;
 Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
 Xaa at position 98 is Thr, Val, or Gln;
 15 Xaa at position 100 is Tyr or Trp;
 Xaa at position 101 is Leu or Ala;
 Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His,
 Met, Phe, Tyr or Ile;
 Xaa at position 103 is Thr or Ser;
 20 Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
 Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
 Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His,
 Ile, Tyr, or Cys;
 Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
 25 which can additionally have Met- or Met-Ala- preceding the amino
 acid in position 1; and wherein from 4 to 35 of the amino acids
 designated by Xaa are different from the corresponding amino acids
 of native human interleukin-3.

30

10. A (15-125)human interleukin-3 mutant polypeptide
 according to Claim 7 of the Formula VIII:

Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa
 35 1 5 10 15

Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp

25

30

Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu
 35 40 45

5

Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile
 50 55 60

10

Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr
 65 70 75

Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp
 80 85 90

15

Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu
 95 100 105

Xaa Xaa Xaa Xaa Gln Gln [SEQ ID NO:22]
 110

20

wherein

Xaa at position 3 is Ser, Gly, Asp, or Gln;

Xaa at position 4 is Asn, His, or Ile;

Xaa at position 9 is Ile, Ala, Leu, or Gly;

Xaa at position 11 is Thr, His, or Gln;

25

Xaa at position 12 is His or Ala;

Xaa at position 15 is Gln or Asn;

Xaa at position 16 is Pro or Gly;

Xaa at position 18 is Leu, Arg, Asn, or Ala;

Xaa at position 20 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile,

30

Phe, Thr or Met;

Xaa at position 21 is Leu, Ala, Asn, or Pro;

Xaa at position 24 is Asn or Ala;

Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met,
 Tyr or Arg;

35

Xaa at position 31 is Gln, Val, Met, Leu, Ala, Asn, Glu or Lys;

Xaa at position 32 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val
 or Thr;

- Xaa at position 36 is Glu, Asn, Ser or Asp;
- Xaa at position 37 is Asn, Arg, Pro, Thr, or His;
- Xaa at position 41 is Arg, Leu, or Gly;
- Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
- 5 Xaa at position 48 is Asn, Pro, or Thr;
- Xaa at position 50 is Ala or Asn;
- Xaa at position 51 is Val or Thr;
- Xaa at position 53 is Ser or Phe;
- Xaa at position 54 is Leu or Phe;
- 10 Xaa at position 55 is Gln, Ala, Glu, or Arg;
- Xaa at position 62 is Ser, Val, Asn, Pro, or Gly;
- Xaa at position 63 is Ile or Leu;
- Xaa at position 65 is Lys, Asn, Met, Arg, Ile, or Gly;
- Xaa at position 66 is Asn, Gly, Glu, or Arg;
- 15 Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His,
Met, Phe, Ser, Thr, Tyr or Val;
- Xaa at position 73 is Leu or Ser;
- Xaa at position 74 is Ala or Trp;
- Xaa at position 77 is Ala or Pro;
- 20 Xaa at position 79 is Thr, Asp, or Ala;
- Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
- Xaa at position 84 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu,
Lys, Met, Ser, Tyr, Val or Leu;
- Xaa at position 85 is Ile or Leu;
- 25 Xaa at position 86 is Lys or Arg;
- Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, Ile, Leu
or Tyr;
- Xaa at position 91 is Asn, Pro, Ser, Ile or Asp;
- Xaa at position 94 is Arg, Ala, or Ser;
- 30 Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
- Xaa at position 98 is Thr or Gln;
- Xaa at position 102 is Lys, Val, Trp, or Ile;
- Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser;
- Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
- 35 Xaa at position 107 is Ala, Ser, Ile, Pro, or Asp;
- Xaa at position 108 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
- Xaa at position 109 is Ala, Met, Glu, Ser, or Leu;

and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from 4 to 26 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3; or a polypeptide having

5 substantially the same structure and substantially the same biological activity.

11. A (15-125) human interleukin-3 mutant polypeptide

10 of claim 7 wherein:

Xaa at position 17 is Ser, Lys, Asp, Met, Gln, or Arg;
 Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
 Xaa at position 19 is Met, Arg, Gly, Ala, or Cys;
 15 Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
 Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, or Val;
 Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, or Gly;
 Xaa at position 23 is Ile, Ala, Gly, Trp, Lys, Leu, Ser, or Arg;
 Xaa at position 24 is Ile, Gly, Arg, or Ser;
 20 Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
 Xaa at position 26 is His, Thr, Phe, Gly, Ala, or Trp;
 Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
 Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, Val or Trp;
 Xaa at position 29 is Gln, Asn, Loh, Pro, Arg, or Val;
 25 Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
 Xaa at position 31 is Pro, Asp, Gly, Arg, Leu, or Gln;
 Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
 Xaa at position 33 is Pro, Leu, Gln, Thr, or Glu;
 30 Xaa at position 34 is Leu, Gly, Ser, or Lys;
 Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, or Gln;
 Xaa at position 36 is Asp, Leu, or Val;
 Xaa at position 37 is Phe, Ser, or Pro;
 Xaa at position 38 is Asn, or Ala;
 35 Xaa at position 40 is Leu, Trp, or Arg;
 Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, Pro;
 Xaa at position 42 is Gly, Asp, Ser, Cys, or Ala;

- Xaa at position 42 is Glu, Asn, Tyr, Leu, Phe, Trp, Ala, Cys, or Ser;
- Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, or Pro;
- 5 Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, or Trp;
- Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, or Gly;
- Xaa at position 47 is Ile, Gly, Ser, Arg, Pro, or His;
- Xaa at position 48 is Leu, Ser, Cys, Arg, His, Phe, or Asn;
- 10 Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
- Xaa at position 50 is Glu, Leu, Thr, Asp, or Tyr;
- Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
- Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
- Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or;
- 15 Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, or Leu;
- Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;
- Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, or Lys;
- Xaa at position 57 is Asn or Gly;
- Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
- 20 Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;
- Xaa at position 60 is Ala, Ser, Tyr, Asn, or Thr;
- Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
- Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, or Ile;
- Xaa at position 63 is Arg, Tyr, Trp, Ser, Pro, or Val;
- 25 Xaa at position 64 is Ala, Asn, Ser, or Lys;
- Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;
- Xaa at position 66 is Lys, Ile, Val, Asn, Glu, or Ser;
- Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
- 30 Xaa at position 68 is Leu, Val, Trp, Ser, Thr, or His;
- Xaa at position 69 is Gln, Ala, Pro, Thr, Arg, Trp, Gly, or Leu;
- Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;
- Xaa at position 71 is Ala, Met, Leu, Arg, Glu, Thr, Gln, Trp, or Asn;
- 35 Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
- Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
- Xaa at position 74 is Ile, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Thr, Arg, Ser, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

5 Xaa at position 77 is Ile, Ser, Arg, or Thr;

Xaa at position 78 is Leu, Ala, Ser, Glu, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Ile, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, or Arg;

10 Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, or Lys;

Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, or Asp;

Xaa at position 83 is Pro, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, or Gln;

15 Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, or Asn;

Xaa at position 90 is Ala, Ser, Asp, Ile, or Met;

20 Xaa at position 91 is Ala, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, or Pro;

Xaa at position 95 is His, Gln, Pro, Val, Leu, Thr or Tyr;

25 Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;

Xaa at position 97 is Ile, Lys, Ala, or Asn;

Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, or Pro;

Xaa at position 99 is Ile, Arg, Asp, Pro, Gln, Gly, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Ile, Ser, Gln, or Pro;

30 Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, or Gln;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,

35 Gln, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, or His;

Xaa at position 107 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
 Xaa at position 108 is Arg, Asp, Leu, Thr, Ile, or Pro;
 Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly.

5 12. The human interleukin-3 mutant polypeptide of claim
 7:

wherein;

Xaa at position 28 is Gly, Asp, Ser, Ile, Leu, Met, Tyr, or Ala;
 10 Xaa at position 31 is Gln, Val, Met or Asn;
 Xaa at position 32 is Asp, Ser, Ala, Gln, His or Val;
 Xaa at position 36 is Glu or Asp;
 Xaa at position 37 is Asn, Pro or Thr;
 Xaa at position 48 is Asn or Pro;
 15 Xaa at position 62 is Ser, or Pro;
 Xaa at position 68 is Leu, Trp, Asp, Asn Glu, His, Phe, Ser or Tyr;
 Xaa at position 81 is His, Arg, Thr, Asn or Ser;
 Xaa at position 84 is His, Ile, Leu, Ala, Arg, Gln, Lys, Met, Ser,
 Tyr or Val;
 20 Xaa at position 86 is Lys or Arg;
 Xaa at position 87 is Asp, Pro, His, Asn, Ile or Leu;
 Xaa at position 91 is Asn, or Pro;
 Xaa at position 94 is Arg, Ala, or Ser;
 Xaa at position 102 is Lys, Val, Trp, Ala, His, Phe, or Tyr;
 25 Xaa at position 107 is Ala, or Ile;
 Xaa at position 108 is Gln, or Ile; and
 Xaa at position 109 is Ala, Met or Glu.

30 13. A polypeptide of the formula

| | | | | | |
|----|---|-----|-----|-----|-----------------------------|
| | 1 | | 5 | | 10 |
| | (Met) _m -Ala | Pro | Met | Thr | Gln Thr Thr Ser Leu Lys Thr |
| | | 15 | | 20 | |
| | Ser Trp Val Asn Cys Ser Xaa Xaa Xaa Asp Glu Ile Ile | | | | |
| 35 | 25 | | 30 | | 35 |
| | Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa | | | | |
| | 40 | | 45 | | 50 |

Xaa Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Xaa Glu
 55 60
 Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa
 65 70 75
 5 Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
 80 85
 Ile Leu Xaa Asn Leu Xaa Pro Cys Xaa Pro Xaa Xaa Thr
 90 95 100
 Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly
 10 105 110 115
 Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu
 120 125
 Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu
 130
 15 Ser Leu Ala Ile Phe [SEQ ID NO:129]

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile;
 Xaa at position 19 is Met, Ala or Ile; Xaa at position 20
 is Ile, Pro or Ile; Xaa at position 23 is Ile, Ala or
 20 Leu; Xaa at position 25 is Thr or His; Xaa at position 29
 is Gln, Arg, Val or Ile; Xaa at position 32 is Leu, Ala,
 Asn or Arg; Xaa at position 34 is Leu or Ser; Xaa at
 position 37 is Phe, Pro, or Ser; Xaa at position 38 is
 Asn or Ala; Xaa at position 42 is Gly, Ala, Ser, Asp or
 25 Asn; Xaa at position 45 is Gln, Val, or Met; Xaa at
 position 46 is Asp or Ser; Xaa at position 49 is Met,
 Ile, Leu or Asp; Xaa at position 50 is Glu or Asp; Xaa at
 position 51 is Asn Arg or Ser; Xaa at position 55 is Arg,
 Leu, or Thr; Xaa at position 56 is Pro or Ser; Xaa at
 30 position 59 is Glu or Leu; Xaa at position 60 is Ala or
 Ser; Xaa at position 62 is Asn, Val or Pro; Xaa at
 position 63 is Arg or His; Xaa at position 65 is Val or
 Ser; Xaa at position 67 is Ser, Asn, His or Gln; Xaa at
 position 69 is Gln or Glu; Xaa at position 73 is Ala or
 35 Gly; Xaa at position 76 is Ser, Ala or Pro; Xaa at
 position 79 is Lys, Arg or Ser; Xaa at position 82 is
 Leu, Glu, Val or Trp; Xaa at position 85 is Leu or Val;
 Xaa at position 87 is Leu, Ser, Tyr; Xaa at position 88

is Ala or Trp; Xaa at position 91 is Ala or Pro; Xaa at position 93 is Pro or Ser; Xaa at position 95 is His or Thr; Xaa at position 98 is His, Ile, or Thr; Xaa at position 100 is Lys or Arg; Xaa at position 101 is Asp, 5 Ala or Met; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg, Glu or Leu; Xaa at position 112 is Thr or Gln; Xaa at position 116 is Lys, Val, Trp or Ser; Xaa at position 117 is Thr or Ser; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; with 10 the proviso that from four to forty-four of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

15

14. A polypeptide according to Claim 13 wherein Xaa at position 18 is Ile; Xaa at position 19 is Ala, or Ile; Xaa at position 20 is Pro, or Leu; Xaa at position 23 is Ala, or Leu; Xaa at position 25 is His; 20 Xaa at position 29 is Arg, Val, or Ile; Xaa at position 32 is Ala, Asn or Arg; Xaa at position 34 is Ser; Xaa at position 37 is Pro or Ser; Xaa at position 38 is Ala; Xaa at position 42 is Ala, Ser, Asp, or Asn; and Xaa at position 45 is Val or Met; Xaa at position 46 is Ser.

25

15. A polypeptide according to Claim 13 wherein Xaa at position 49 is Ile, or Leu, or Asp; Xaa at position 50 is Asp; Xaa at position 51 is Arg or Ser; Xaa at position 55 is Leu or Thr; Xaa at position 56 is Ser; 30 Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Val, or Pro; Xaa at position 63 is His; Xaa at position 65 is Ser; Xaa at position 67 is Asn, or His, or Gln; and Xaa at position 69 is Glu.

35

16. A polypeptide according to Claim 13

wherein Xaa at position 73 is Gly; Xaa at position 76 is Ala, or Pro; Xaa at position 79 is Arg, or Ser; Xaa at position 82 is Gln or Val, or Trp; Xaa at position 85 is Val; Xaa at position 87 is Ser, or Tyr; Xaa at position 5 88 is Trp; Xaa at position 91 is Pro; Xaa at position 93 is Ser; Xaa at position 95 is Thr; Xaa at position 98 is Ile or Thr; Xaa at position 100 is Arg; Xaa at position 101 is Ala, or Met; and Xaa at position 105 is Glu.

17. A polypeptide according to Claim 13
wherein Xaa at position 109 is Glu, or Leu; Xaa at
position 112 is Gln; Xaa at position 116 is Val, or Trp,
or Ser; Xaa at position 117 is Ser; Xaa at position 120
5 is Glu or His; and Xaa at position 123 is Glu.

18. A polypeptide according to Claim 13
wherein Xaa at position 18 is Ile; Xaa at position 19 is
Ala, or Ile; Xaa at position 20 is Pro, or Leu; Xaa at
10 position 23 is Ala, or Leu; Xaa at position 25 is His;
Xaa at position 29 is Arg or Val, or Ile; Xaa at position
32 is Ala or Asn, or Arg; Xaa at position 34 is Ser; Xaa
at position 37 is Pro or Ser; Xaa at position 38 is Ala;
Xaa at position 42 is Ala or Ser, Asp or Asn; Xaa at
15 position 45 is Val or Met; Xaa at position 46 is Ser; Xaa
at position 49 is Ile, or Leu, or Asp; Xaa at position 50
is Asp; Xaa at position 51 is Arg, or Ser; Xaa at
position 55 is Leu or Thr; Xaa at position 56 is Ser; Xaa
at position 59 is Glu or Leu; Xaa at position 60 is Ala
20 or Ser; Xaa at position 62 is Val, or Pro; Xaa at
position 63 is His; Xaa at position 65 is Ser; Xaa at
position 67 is Asn, or His, or Gln; and Xaa at position
69 is Glu.

25 19. A polypeptide according to Claim 13
wherein Xaa at position 73 is Gly; Xaa at position 76 is
Ala, or Pro; Xaa at position 79 is Arg, or Ser; Xaa at
position 82 is Gln or Val, or Trp; Xaa at position 85 is
Val; Xaa at position 87 is Ser, or Tyr; Xaa at position
30 88 is Trp; Xaa at position 91 is Pro; Xaa at position 93
is Ser; Xaa at position 95 is Thr; Xaa at position 98 is
Ile or Thr; Xaa at position 100 is Arg; Xaa at position
101 is Ala, or Met; Xaa at position 105 is Glu; Xaa at
position 109 is Glu, or Leu; Xaa at position 112 is Gln;
35 Xaa at position 116 is Val, or Trp, or Ser; Xaa at
position 117 is Ser; Xaa at position 120 is Glu or His;
and Xaa at position 123 is Glu.

20. A polypeptide of the formula

| | | | |
|----|--|-----|-----|
| | 1 | 5 | 10 |
| | (Met _m -Alan) _p -Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa Ile | | |
| 5 | 15 | 20 | |
| | Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa | | |
| | 25 | 30 | 35 |
| | Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu Xaa Glu | | |
| 10 | 40 | 45 | |
| | Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa | | |
| | 50 | 55 | 60 |
| | Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa | | |
| | 65 | 70 | 75 |
| 15 | Ile Leu Xaa Asn Xaa Xaa Pro Cys Xaa Pro Xaa Ala Thr | | |
| | 80 | 85 | |
| | Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly | | |
| | 90 | 95 | 100 |
| | Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu | | |
| 20 | 105 | 110 | |
| | Xaa Xaa Leu Glu Xaa Ala Gln Xaa Gln Gln [SEQ ID NO:130] | | |

wherein m is 0 or 1; n is 0 or 1; p is 0 or 1; Xaa at position 4 is Asn or Ile; Xaa at position 5 is Met, Ala or Ile; Xaa at position 6 is Ile, Pro or Leu; Xaa at position 9 is Ile, Ala or Leu; Xaa at position 11 is Thr or His; Xaa at position 15 is Gln, Arg, Val or Ile; Xaa at position 18 is Leu, Ala, Asn or Arg; Xaa at position 20 is Leu or Ser; Xaa at position 23 is Phe, Pro, or Ser; Xaa at position 24 is Asn or Ala; Xaa at position 28 is Gly, Ala, Ser, Asp or Asn; Xaa at position 31 is Gln, Val, or Met; Xaa at position 32 is Asp or Ser; Xaa at position 35 is Met, Ile or Asp; Xaa at position 36 is Glu or Asp; Xaa at position 37 is Asn, Arg or Ser; Xaa at position 41 is Arg, Leu, or Thr; Xaa at position 42 is Pro or Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Asn, Val

or Pro; Xaa position 49 is Arg or His; Xaa at position 51 is Val or Ser; Xaa at position 53 is Ser, Asn, His or Gln; Xaa at position 55 is Gln or Glu; Xaa at position 59 is Ala or Gly; Xaa at position 62 is Ser, Ala or Pro; Xaa at position 65 is Lys, Arg or Ser; Xaa at position 67 is Leu, Glu, or Val; Xaa at position 68 is Leu, Glu, Val or Trp; Xaa at position 71 is Leu or Val; Xaa at position 73 is Leu, Ser or Tyr; Xaa at position 74 is Ala or Trp; Xaa at position 77 is Ala or Pro; Xaa at position 79 is Pro or Ser; Xaa at position 81 is His or Thr; Xaa at position 84 is His, Ile, or Thr; Xaa at position 86 is Lys or Arg; Xaa at position 87 is Asp, Ala or Met; Xaa at position 91 is Asn or Glu; Xaa at position 95 is Arg, Glu, Leu; Xaa at position 98 Thr or Gln; Xaa at position 102 is Lys, Val, Trp or Ser; Xaa at position 103 is Thr or Ser; Xaa at position 106 is Asn, Gln, or His; Xaa at position 109 is Ala or Glu; with the proviso that from four to forty-four of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.

21. A polypeptide according to Claim 20 wherein Xaa at position 4 is Ile; Xaa at position 5 is Ala, or Ile; Xaa at position 6 is Pro, or Leu; Xaa at position 9 is Ala, or Leu; Xaa at position 11 is His; Xaa at position 15 is Arg or Val, or Ile; Xaa at position 18 is Ala or Asn, or Arg; Xaa at position 20 is Ser; Xaa at position 23 is Pro or Ser; Xaa at position 24 is Ala; Xaa at position 28 is Ala or Ser, or Asp, or Asn; Xaa at position 31 is Val or Met; and Xaa at position 32 is Ser.

22. A polypeptide according to Claim 20 wherein Xaa at position 35 is Ile, or Leu, or Asp; Xaa at position 36 is Asp; Xaa at position 37 is Arg, or Ser; Xaa at position 41 is Leu or Thr; Xaa at position 42 is

Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Val, or Pro; Xaa at position 49 is His; Xaa at position 51 is Ser; Xaa at position 53 is Asn, or His, or Gln; and Xaa at position 55 is Glu.

23. A polypeptide according to Claim 20 wherein Xaa at position 59 is Gly; Xaa at position 62 is Ala, or Pro; Xaa at position 65 is Arg, or Ser; Xaa at position 67 is Gln or Val; Xaa at position 68 is Glu, or Val, or Trp; Xaa at position 71 is Val; Xaa at position 73 is Ser, or Tyr; Xaa at position 74 is Trp; Xaa at position 77 is Pro; Xaa at position 79 is Ser; Xaa at position 81 is Thr; Xaa at position 84 is Ile or Thr; Xaa at position 86 is Arg; Xaa at position 87 is Ala, or Met; and Xaa at position 91 is Glu.

24. A polypeptide according to Claim 20 wherein Xaa at position 95 is Glu, or Leu; Xaa at position 98 is Gln; Xaa at position 102 is Val, or Trp, or Ser; Xaa at position 103 is Ser; Xaa at position 106 is Glu or His; and Xaa at position 109 is Glu.

25. A polypeptide according to Claim 20 wherein Xaa at position 4 is Ile; Xaa at position 5 is Ala, or Ile; Xaa at position 6 is Pro, or Leu; Xaa at position 9 is Ala, or Leu; Xaa at position 11 is His; Xaa at position 15 is Arg or Val, or Ile; Xaa at position 18 is Ala or Asn, or Arg; Xaa at position 20 is Ser; Xaa at position 23 is Pro or Ser; Xaa at position 24 is Ala; Xaa at position 28 is Ala or Ser, or Asp, or Asn; Xaa at position 31 is Val or Met; Xaa at position 32 is Ser; Xaa at position 35 is Ile, or Leu, or Asp; Xaa at position 36 is Asp; Xaa at position 37 is Arg, or Ser; Xaa at position 41 is Leu or Thr; Xaa at position 42 is Ser; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Val, or Pro; Xaa at

position 49 is His; Xaa at position 51 is Ser; Xaa at position 53 is Asn, or His, or Gln; and Xaa at position 55 is Glu.

5 26. A polypeptide according to Claim 20
 wherein Xaa at position 59 is Gly; Xaa at position 62 is
 Ala, or Pro; Xaa at position 65 is Arg, or Ser; Xaa at
 position 67 is Gln or Val; Xaa at position 68 is Glu, or
 Val, or Trp; Xaa at position 71 is Val; Xaa at position
 10 73 is Ser, or Tyr; Xaa at position 74 is Trp; Xaa at
 position 77 is Pro; Xaa at position 79 is Ser; Xaa at
 position 81 is Thr; Xaa at position 84 is Ile or Thr; Xaa
 at position 86 is Arg; Xaa at position 87 is Ala, or Met;
 Xaa at position 91 is Glu; Xaa at position 95 is Glu, or
 15 Lue; Xaa at position 98 is Gln; Xaa at position 102 is
 Val, or Trp, or Ser; Xaa at position 103 is Ser; Xaa at
 position 106 is Glu or His; and Xaa at position 109 is
 Glu.

20 27. A polypeptide according to Claim 20 which
 is selected from

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
 Ala
 25 Glu Asp Val Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro
 Asn
 Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
 Ser
 Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro
 30 Leu
 Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
 Gly
 Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
 Thr
 35 Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:66];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu

Lys
 Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
 Glu
 Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
 5 Leu
 Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
 Ala
 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
 Ala
 10 Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
 Asp
 Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
 Leu
 Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:67];
 15
 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
 Lys
 Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
 Glu
 20 Asp Met Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
 Leu
 Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
 Ala
 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
 25 Ala
 Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
 Asp
 Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
 Leu
 30 Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:68];
 Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
 Lys
 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
 35 Glu
 Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
 Leu

Leu Ala Phe Arg Ala Val Lys Asn Leu Asn Ala Ser
Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
5 Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:69];
10 Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu
15 Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu
Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
20 Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
25 Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:70];
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
Lys
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
30 Glu
Asp Gln Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu
Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
Ala
35 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly

Asp

Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu

Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:71];

5

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu

10 Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu

Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly

Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser

15 Ala

Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
Asp

Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu

20 Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:72];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
25 Glu

Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu

Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Gly

30 Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
Ala

Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
Asp

Trp Gln Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
35 Leu

Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:73];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu

5 Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu

Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala

10 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala

Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp

Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
Leu

15 Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:74];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys

Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
20 Glu

Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
Leu

Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala

25 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala

Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp

30 Trp Asn Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
Leu

Glu His Ala Gln Glu Gln Gln [SEQ ID NO:75];

Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu

Lys

35 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
Glu

Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn

Leu
 Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
 Gly
 Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser
 5 Ala
 Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly
 Asp
 Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
 Leu
 10 Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:76];

 Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
 Lys
 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
 15 Glu
 Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
 Leu
 Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
 Gly
 20 Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
 Ala
 Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala Gly
 Asp
 Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr
 25 Leu
 Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:77];

 Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
 Lys
 30 Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly
 Glu
 Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn
 Leu
 Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
 35 Gly
 Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro Ser
 Ala

Thr Ala Ala Pro Ser Arg His Pro Ile Thr Leu Lys Ala Gly
Asp
Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Ser
Leu
5 Glu His Ala Gln Glu Gln Gln [SEQ ID NO:78];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys
Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala
10 Glu
Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
Leu
Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
Ala
15 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
20 Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:79];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
Lys
25 Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu
Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
Leu
Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser
30 Ala
Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
Ala
Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
Asp
35 Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
Leu
Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:80];

Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
 Lys
 Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser
 5 Glu
 Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn
 Leu
 Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser
 Ala
 10 Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu
 Ala
 Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp Gly
 Asp
 Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr
 15 Leu
 Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:81];

 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His
 Leu
 20 Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn
 Gly
 Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro
 Asn
 Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
 25 Ser
 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
 Ser
 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
 Gly
 30 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
 Thr
 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:82];

 Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His
 35 Leu
 Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn
 Gly

Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro
Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
Ser
5 Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
10 Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:83];

Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His
Leu
15 Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn
Gly
Glu Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro
Asn
Leu Glu Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
20 Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
Gly
25 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:84];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
30 Leu
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ala
Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn
35 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro

Leu
 Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
 Gly
 Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
 5 Thr
 Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:85];

 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 Leu
 10 Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
 Ser
 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
 Asn
 Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
 15 Ser
 Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro
 Leu
 Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
 Gly
 20 Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
 Thr
 Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:86];

 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 25 Leu
 Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn
 Ser
 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
 Asn
 30 Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 Ser
 Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro
 Leu
 Ala Thr Ala Ala Pro Thr Arg His Pro Ile His Ile Lys Asp
 35 Gly
 Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr Phe Tyr Leu Lys
 Thr

Leu Glu Asn Ala Gln Ala Gln Gln [SEQ ID NO:87];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu

5 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn

10 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly

15 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:88];

20 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
Asn

25 Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser

30 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:89];

35 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu

Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn

Ser
 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
 Asn
 Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 5 Ser
 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
 Ser
 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
 Gly
 10 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
 Thr
 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:90];

 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 15 Leu
 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
 Ala
 Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
 Asn
 20 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 Ser
 Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
 Ser
 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
 25 Gly
 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
 Thr
 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:91];

 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 30 Leu
 Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn
 Ser
 Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
 35 Asn
 Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
Gly
5 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr
Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:92];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
10 Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
Asn
15 Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
Ser
Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
20 Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Ser
Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:93];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
25 Leu
Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
30 Asn
Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro
Ser
35 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala
Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:94];

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His

5 Leu

Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn

Ser

Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro

Asn

10 Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala

Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro

Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala

15 Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO:95]; and

20 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His

Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn

Ala

Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro

25 Asn

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala

Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Val Pro Cys Leu Pro

Ser

30 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Thr Ile Lys Ala

Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Ser

Leu Glu His Ala Gln Glu Gln Gln [SEQ ID NO:96].

35

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His

Leu

40 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn

Ala

Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Ser
Asn

5

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser

10 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser

Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly

15 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 296]

20 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ala Ile His His
Leu

Lys Arg Pro Pro Ala Pro Ser Leu Asp Pro Asn Asn Leu Asn
Asp

25 Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn

30 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser

35 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly

Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

40 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 300]

45 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
Asp

50 Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn

55 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
 Ser
 5 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
 Gly
 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
 Thr
 10 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 301]
 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 Leu
 15 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
 Ala
 Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Pro
 20 Asn
 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 Ser
 25 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
 Ser
 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
 Gly
 30 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
 Thr
 Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 308]
 35 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
 Leu
 40 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
 Asp
 Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
 Asn
 45 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
 Ser
 Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
 50 Ser
 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
 Gly
 55 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 309]

5

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu10 Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn
AspGlu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro
Asn15 Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala
SerGly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser20 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly25 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 310]

30 Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys
AsnCys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro35 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp
ValAsp Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu
Ser40 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile
Glu45 Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr
AlaAla Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gln50 Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gln

Ala Gln Glu Gln Gln [SEQ ID NO.: 315]

55

Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp Lys
Asn

5 Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg
Pro

Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp
Met

10 Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu
Ala

Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile
Glu

15 Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro Ser Ala Thr
Ala

20 Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp
Gln

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu
Gln

25 Ala Gln Glu Gln Gln [SEQ ID NO.: 316]

Met Ala Asn Cys Ser Ile Met Ile Asp Glu Leu Ile His His
Leu

30 Lys Ile Pro Pro Asn Pro Ser Leu Asp Ser Ala Asn Leu Asn
Ser

Glu Asp Val Ser Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
Asn

35 Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
Ser

Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser

40 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly

45 Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID NO.: 318]

50 28. A pharmaceutical composition for the
treatment of hematopoietic cell deficiencies comprising a
therapeutically effective amount of a mutant human

interleukin- polypeptide selected from group
consisting of a polypeptide of claim 1, a polypeptide of
claim 2, a polypeptide of claim 3, a polypeptide of claim
4, a polypeptide of claim 5, a polypeptide of claim 6, a
5 polypeptide of claim 7, a polypeptide of claim 8, a
polypeptide of claim 9, a polypeptide of claim 10, a
polypeptide of claim 11, a polypeptide of claim 12, a
polypeptide of claim 13, a polypeptide of claim 14, a
polypeptide of claim 15, a polypeptide of claim 16, a
10 polypeptide of claim 17; a polypeptide of claim 18, a
polypeptide of claim 19, a polypeptide of claim 20, a
polypeptide of claim 21, a polypeptide of claim 22, a
polypeptide of claim 23, a polypeptide of claim 24, a
polypeptide of claim 25, a polypeptide of claim 26 and a
15 polypeptide of claim 27, and a pharmaceutically
acceptable carrier.

29. A pharmaceutical composition according to
20 Claim 28 for the treatment of hematopoietic cell
deficiencies comprising a therapeutically effective
amount of a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:88 and a pharmaceutically
acceptable carrier.

25

30. A pharmaceutical composition according to
Claim 28 for the treatment of hematopoietic cell
deficiencies comprising a therapeutically effective
amount of a polypeptide having an amino acid sequence
30 corresponding to SEQ ID NO:89 and a pharmaceutically
acceptable carrier.

31. A pharmaceutical composition according to
Claim 28 for the treatment of hematopoietic cell
35 deficiencies comprising a therapeutically effective
amount of a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:90 and a pharmaceutically

acceptable carrier.

32. A pharmaceutical composition according to
Claim 28 for the treatment of hematopoietic cell
5 deficiencies comprising a therapeutically effective
amount of a polypeptide selected from the group
consisting of

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:66;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:67;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:68;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:69;

20

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:70;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:71;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:72;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:73;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:74;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:75;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:76;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:77;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:78;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:79;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:80;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:81;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:82;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:83;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:84;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:85;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:86;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:87;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:91;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:92;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:93;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:94;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:95;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:96;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:258;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:259;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:260;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:261;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:262;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:263;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:278;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:279;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:314;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:315;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:316;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:264;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:265;

5

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:266;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:267;

10

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:268;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:269;

15

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:270;

20

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:271;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:272;

25

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:273;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:274;

30

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:275;

35

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:276;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:277;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:280;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:281;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:282;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:283;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:284;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:285;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:286;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:287;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:288;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:289;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:299;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:300;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:301;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:302;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:303;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:304;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:305;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:306;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:307;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:308;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:309;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:310;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:311;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:312;

5

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:313;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:314;

10

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:317;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:318;

15

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:319;

20

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:320;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:321;

25

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:322;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:323;

30

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:324;

35

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:325;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:326;

and a pharmaceutically acceptable carrier.

5

33. A method of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a mutant human interleukin-3 polypeptide selected from the group consisting of a polypeptide of claim 1, a polypeptide of claim 2, a polypeptide of claim 3, a polypeptide of claim 4, a polypeptide of claim 5, a polypeptide of claim 6, a polypeptide of claim 7, a polypeptide of claim 8, a polypeptide of claim 9, a polypeptide of claim 10, a polypeptide of claim 11, a polypeptide of claim 12, a polypeptide of claim 13, a polypeptide of claim 14, a polypeptide of claim 15, a polypeptide of claim 16, a polypeptide of claim 17; a polypeptide of claim 18, a polypeptide of claim 19, a polypeptide of claim 20, a polypeptide of claim 21, a polypeptide of claim 22, a polypeptide of claim 23, a polypeptide of claim 24, a polypeptide of claim 25, a polypeptide of claim 26, a polypeptide of claim 27, to a patient in need of such treatment.

34. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88.

35. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:89.

36. A method according to claim 33 of stimulating the production of hematopoietic cells which comprises administering a therapeutically effective

amount of a polypeptide having an amino acid sequence corresponding to SEQ ID NO:90.

37. A method according to claim 33 of
- 5 stimulating the production of hematopoietic cells which comprises administering a therapeutically effective amount of a polypeptide selected from the group consisting of
- 10 a polypeptide having an amino acid sequence corresponding to SEQ ID NO:66;
- a polypeptide having an amino acid sequence corresponding to SEQ ID NO:67;
- 15 a polypeptide having an amino acid sequence corresponding to SEQ ID NO:68;
- a polypeptide having an amino acid sequence corresponding to SEQ ID NO:69;
- 20 a polypeptide having an amino acid sequence corresponding to SEQ ID NO:70;
- 25 a polypeptide having an amino acid sequence corresponding to SEQ ID NO:71;
- a polypeptide having an amino acid sequence corresponding to SEQ ID NO:72;
- 30 a polypeptide having an amino acid sequence corresponding to SEQ ID NO:73;
- a polypeptide having an amino acid sequence corresponding to SEQ ID NO:74;
- 35 a polypeptide having an amino acid sequence corresponding to

SEQ ID NO:75;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:76;

5

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:77;

10

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:78;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:79;

15

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:80;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:81;

20

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:82;

25

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:83;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:84;

30

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:85;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:86;

35

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:87;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:91;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:92;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:93;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:94;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:95;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:96;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:258;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:259;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:260;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:261;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:262;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:263;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:278;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:279;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:314;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:315;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:316;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:264;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:265;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:266;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:267;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:268;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:269;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:270;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:271;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:272;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:273;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:274;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:275;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:276;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:277;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:280;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:281;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:282;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:283;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:284;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:285;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:286;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:287;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:288;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:289;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:299;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:300;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:301;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:302;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:303;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:304;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:305;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:306;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:307;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:308;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:309;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:310;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:311;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:312;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:313;

25 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:314;

30 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:317;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:318;

35 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:319;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:320;

5 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:321;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:322;

10 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:323;

15 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:324;

a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:325;

20 a polypeptide having an amino acid sequence corresponding to
SEQ ID NO:326;

to a patient in need of such treatment.

25 38. A recombinant DNA sequence comprising
vector DNA and a DNA that encodes a polypeptide selected from
the group consisting of a polypeptide of claim 1, a polypeptide of
claim 2, a polypeptide of claim 3, a polypeptide of claim 4, a
polypeptide of claim 5, a polypeptide of claim 6, a polypeptide of
30 claim 7, a polypeptide of claim 8, a polypeptide of claim 9, a
polypeptide of claim 10, a polypeptide of claim 11, a polypeptide
of claim 12, a polypeptide of claim 13, a polypeptide of claim 14,
a polypeptide of claim 15, a polypeptide of claim 16, a polypeptide
of claim 17; a polypeptide of claim 18, a polypeptide of claim 19,
35 a polypeptide of claim 20, a polypeptide of claim 21, a polypeptide
of claim 22, a polypeptide of claim 23, a polypeptide of claim 24,
a polypeptide of claim 25, a polypeptide of claim 26, or a

polypeptide of claim 27,.

39. A recombinant DNA sequence according to
Claim 38 comprising vector DNA and a DNA having a
5 nucleotide sequence corresponding to SEQ ID NO:97.

40. A recombinant DNA sequence according to
Claim 38 comprising vector DNA and a DNA having a
nucleotide sequence corresponding to SEQ ID NO:100 or
10 103.

41. A recombinant DNA sequence according to
Claim 38 comprising vector DNA and a DNA having a
nucleotide sequence corresponding to SEQ ID NO:161.
15

42. A recombinant DNA sequence according to
Claim 38 comprising vector DNA and a DNA selected from

a DNA having a nucleotide sequence corresponding to SEQ ID
20 NO:98;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:99;

25 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:101;

a DNA having a nucleotide sequence corresponding to SEQ ID
30 NO:102;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:104;

35 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:105;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:106;

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:107;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:108;

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:109;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:110;

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:111;

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:112;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:113;

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:114;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:115;

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:116;

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:117;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:118;

5 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:119;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:120;

10 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:121;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:122;

15 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:123;

20 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:124;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:125;

25 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:126;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:127;

30 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:160;

35 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:161;

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:398;

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:399;

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:346;

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:347

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:303

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:404

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:405

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:332

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:333

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:334

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:335

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:336

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:337

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:338

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:339

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:340

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:341

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:342

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:343

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:344

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:345

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:348

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:349

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:350

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:352

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:353

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:354

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:355

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:356

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:357

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:358

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:359

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:360

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:361

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:362

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:363

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:364

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:365

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:366

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:367

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:368

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:369

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:370

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:371

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:372

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:373

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:374

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:375

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:376

5

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:377

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:378

10

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:379

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:380

15

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:381

20

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:382

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:384

25

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:385

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:386

30

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:387

35

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:388

a DNA having a nucleotide sequence corresponding to SEQ ID

NO:389

5 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:390

a DNA having a nucleotide sequence corresponding to SEQ ID
NO:391

10 a DNA having a nucleotide sequence corresponding to SEQ ID
NO:392

15 43. A host cell containing a recombinant DNA
sequence of claim 38 and capable of expressing the
encoded polypeptide.

20 44. A host cell of claim 43 containing a
recombinant DNA vector comprising vector DNA and a DNA
having a nucleotide sequence corresponding to SEQ ID
NO:97 and capable of expressing the encoded polypeptide.

25 45. A host cell of claim 43 containing a
recombinant DNA vector comprising vector DNA and a DNA
having a nucleotide sequence corresponding to SEQ ID
NO:100 or 103 and capable of expressing the encoded
polypeptide.

30 46. A host cell of claim 43 containing a
recombinant DNA vector comprising vector DNA and a DNA
having a nucleotide sequence corresponding to SEQ ID
NO:161 and capable of expressing the encoded polypeptide.

35 47. A method of producing a mutant human
interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant

DNA sequence comprising vector DNA and a DNA sequence of Claim 38 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

5

(b) harvesting the polypeptide from the culture.

48. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

15 (a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:97 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

20 (b) harvesting the polypeptide from the culture.

49. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

25 (a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:100 or 103 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

30 (b) harvesting the polypeptide from the culture.

50. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

51. A vector containing a gene having a DNA sequence selected from the group consisting of:

a DNA having a nucleotide sequence corresponding to SEQ ID NO:97;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:100;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:103;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:160;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:161;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:404;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:405;

a DNA having a nucleotide sequence corresponding to SEQ ID NO:364;

a DNA having a nucleotide sequence corresponding to
SEQ ID NO:368;

5 a DNA having a nucleotide sequence corresponding to
SEQ ID NO:369;

a DNA having a nucleotide sequence corresponding to
SEQ ID NO:376;

10 a DNA having a nucleotide sequence corresponding to
SEQ ID NO:377;

15 a DNA having a nucleotide sequence corresponding to
SEQ ID NO:378;

a DNA having a nucleotide sequence corresponding to
SEQ ID NO:385;

20 52. A recombinant DNA vector comprising a
promoter, a ribosome binding site, and a signal peptide
directly linked to a DNA sequence encoding a polypeptide
selected from the group consisting of

25 a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:88;

30 a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:89; and

a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:90;

35 said vector being capable of directing expression of said
mutant human interleukin-3 polypeptide.

53. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD.

54. A recombinant DNA vector according to Claim 51 wherein the ribosome binding site is g10-L.

55. A recombinant DNA vector according to Claim 51 wherein the signal peptide is a lamB signal peptide.

56. A recombinant DNA vector according to Claim 51 wherein the signal peptide is the lamB signal peptide depicted in Figure 8.

57. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD and the ribosome binding site is g10-L.

58. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD, the ribosome binding site is g10-L, and the signal peptide is a lamB signal peptide.

59. A recombinant DNA vector according to Claim 51 wherein the promoter is AraBAD, the ribosome binding site is g10-L, and the signal peptide is the lamB signal peptide depicted in Figure 8.

60. A recombinant bacterial host which comprises the vector of Claim 51 wherein said host secretes a mutant human interleukin-3 polypeptide selected from the group consisting of
a polypeptide having an amino acid sequence corresponding to SEQ ID NO:88;

a polypeptide having an amino acid sequence

corresponding to SEQ ID NO:89; and

a polypeptide having an amino acid sequence
corresponding to SEQ ID NO:90.

5

61. A polypeptide of the formula

| | | | |
|----|---|---|-----|
| | 1 | 5 | 10 |
| | (Met) _m -Ala | Pro Met Thr Gln Thr Thr Ser Leu Lys Thr | |
| 10 | 15 | 20 | |
| | Ser Trp Val Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile | | |
| 25 | 30 | 35 | |
| | Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa | | |
| | 40 | 45 | 50 |
| 15 | Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu | | |
| | 55 | 60 | |
| | Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg | | |
| | 65 | 70 | 75 |
| | Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa | | |
| 20 | 80 | 85 | |
| | Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr | | |
| | 90 | 95 | 100 |
| | Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly | | |
| | 105 | 110 | 115 |
| 25 | Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu | | |
| | 120 | 125 | |
| | Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu | | |
| | 130 | | |
| | Ser Leu Ala Ile Phe [SEQ ID NO:129] | | |

30

wherein m is 0 or 1; Xaa at position 18 is Asn or Ile;
Xaa at position 25 is Thr or His; Xaa at position 29 is
Gln, Arg, or Val; Xaa at position 32 is Leu, Ala, or Asn;
Xaa at position 37 is Phe, Pro, or Ser; Xaa at position
35 42 is Glu, Ala, or Ser; Xaa at position 45 is Gln, Val,
or Met; Xaa at position 51 is Asn or Arg; Xaa at position
55 is Arg, Leu, or Thr; Xaa at position 59 is Glu or Leu;

Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn or Val; Xaa at position 67 is Ser, Asn, or His; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser or Ala; Xaa at position 79 is Lys or Arg; Xaa at position 82 is Leu, Glu, or Val; Xaa at position 87 is Leu or Ser; Xaa at position 93 is Pro or Ser; Xaa at position 98 is His, Ile, or Thr; Xaa at position 101 is Asp or Ala; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg or Glu; Xaa at position 116 is Lys or Val; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; with the proviso that from four to twenty-seven of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3 and wherein from 1 to 14 of amino acids 1 to 14 has been deleted from the N-terminus and/or from 1 to 15 of amino acids 119 to 133 has been deleted from the C-terminus of the polypeptide; or a polypeptide having substantially the same structure and substantially the same biological activity.

62. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

(a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:160 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

(b) harvesting the polypeptide from the culture.

63. A method according to Claim 47 of producing a mutant human interleukin-3 polypeptide comprising the steps of:

5 (a) culturing a host cell containing a recombinant DNA sequence comprising vector DNA and a DNA having a nucleotide sequence corresponding to SEQ ID NO:161 and capable of expressing the encoded polypeptide under conditions permitting expression of the recombinant DNA; and

10 (b) harvesting the polypeptide from the culture.

64. A host cell containing a recombinant DNA vector comprising vector DNA and a DNA sequence selected from the group consisting of:

15 a DNA having a nucleotide sequence corresponding to SEQ ID NO:160; and

a DNA having a nucleotide sequence corresponding to SEQ ID NO:161;

20 and capable of expressing the encoded polypeptide.

65. A polypeptide according to Claim 27 which is:

25 Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His
Leu
Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
Ser
Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro
30 Asn
Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala
Ser
Gly Ile Glu Ala Ile Leu Arg Asn Leu Gln Pro Cys Leu Pro
Ser
35 Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala
Gly
Asp Trp Gln Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val
Thr

Leu Glu Gln Ala Gln Glu Gln Gln [SEQ ID:89].

363 10078113.021902

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----------------|-----|-----|-----|-----|-----|-----|-----|
| 1 | ATG | GCT | CCA | ATG | A | 5 | CAG | ACT | ACT | TCT | CTT | AAG | AC | CT |
| | Met | Ala | Pro | Met | Thr | | Gln | Thr | Thr | Ser | Leu | Lys | Thr | Ser |
| 15 | TGG | GTT | AAC | TGC | TCT | AAC | ATG | ATC | GAT | GAA | ATT | ATA | ACA | |
| | Trp | Val | Asn | Cys | Ser | Asn | Met | Ile | Asp | Glu | Ile | Ile | Thr | |
| 30 | CAC | TTA | AAG | CAG | CCA | CCT | TTG | CCT | TTG | CTG | GAC | TTC | AAC | |
| | His | Leu | Lys | Gln | Pro | Pro | Leu | Pro | Leu | Leu | Asp | Phe | Asn | |
| 40 | AAC | CTC | AAT | GGG | GAA | GAC | CAA | GAC | ATT | CTG | ATG | GAA | AAT | |
| | Asn | Leu | Asn | Gly | Glu | Asp | Gln | Asp | Ile | Leu | Met | Glu | Asn | |
| 55 | AAC | CTT | CGA | AGG | CCA | AAC | CTG | GAG | GCA | TTC | AAC | AGG | GCT | |
| | Asn | Leu | Arg | Arg | Pro | Asn | Leu | Glu | Ala | Phe | Asn | Arg | Ala | |
| 65 | GTC | AAG | AGT | TTA | CAG | AAT | GCA | TCA | GCA | ATT | GAG | AGC | ATT | |
| | Val | Lys | Ser | Leu | Gln | Asn | Ala | Ser | Ala | Ile | Glu | Ser | Ile | |
| 80 | CTT | AAA | AAT | CTC | CTG | CCA | TGT | CTG | CCC | CTG | GCC | ACG | GCC | |
| | Leu | Lys | Asn | Leu | Leu | Pro | Cys | Leu | Pro | Leu | Ala | Thr | Ala | |
| 95 | GCA | CCC | ACG | CGA | CAT | CCA | ATC | CAT | ATC | AAG | GAC | GGT | GAC | |
| | Ala | Pro | Thr | Arg | His | Pro | Ile | His | Ile | Lys | Asp | Gly | Asp | |
| 105 | TGG | AAT | GAA | TTC | CGT | CGT | AAA | CTG | ACC | TTC | TAT | CTG | AAA | |
| | Trp | Asn | Glu | Phe | Arg | Arg | Lys | Leu | Thr | Phe | Tyr | Leu | Lys | |
| 120 | ACC | TTG | GAG | AAC | GCG | CAG | GCT | CAA | CAG | ACC | ACT | CTG | TCG | |
| | Thr | Leu | Glu | Asn | Ala | Gln | Ala | Gln | Gln | Thr | Thr | Leu | Ser | |
| 130 | CTA | GCG | ATC | TTT | TAA | TAA | [SEQ ID NO:144] | | | | | | | |
| | Leu | Ala | Ile | Phe | END | END | [SEQ ID NO:128] | | | | | | | |

FIG. 1

C
 I
 a
 I
 aa20 1 ATCGATGAAATCATCACCCACCTGAAGCAGCCACCGCTGCCGCTGCTGGACTTCAACAAC + 60
 1 IleAspGluIleIleThrHisLeuLysGlnProLeuProLeuLeuAspPheAsnAsn -
 E C O R V X h o I
 61 CTCAATGGTGAAGACCAAGATATCCTGATGGAAATAACCTTCGTCGTCCTCCAAACCTCGAG + 120
 61 LeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGlu -
 P N s i I
 121 GCATTCAACCGTGTCTCAAGTCTCTGCAGAATGCAT [SEQ ID NO:145] aa70
 121 AlaPheAsnArgAlaValLysSerLeuGlnAsnAla [SEQ ID NO:146]

FIG. 2: ClaI to NsiI Replacement Fragment

FIG. 2

N
 C
 O
 I

H
 P
 a
 I

1 CCATGGCTCCAATGACTCAGACTACTTCTCTTAAGACTTCTTGGGTAACTGCTCTAACA
 -----+-----+-----+-----+-----+-----+ 60
 GGTACCGAGGTTACTGAGTCTGATGAAGAGAATTCTGAAGAACCAATTGACGAGATTGT
 MetAlaProMetThrGlnThrThrSerLeuLysThrSerTrpValAsnCysSerAsnMet

C
 l
 a
 I

61 TGATCGATGAAATTATAACACACTTAAAGCAGCCACCTTTGCCTTTGCTGGACTTCAACA
 -----+-----+-----+-----+-----+-----+ 120
 ACTAGCTACTTTAATATTGTGTGAATTCGTCGGTGGAAACGGAACGACCTGAAGTTGT
 IleAspGluIleIleThrHisLeuLysGlnProProLeuProLeuLeuAspPheAsnAsn

121 ACCTCAATGGGGAAGACCAAGACATTCTGATGGAAAATAACCTTCGAAGGCCAAACCTGG
 -----+-----+-----+-----+-----+-----+ 180
 TGGAGTTACCCCTTCTGGTTCTGTAAGACTACCTTTTATTGGAAGCTTCCGGTTTGGACC
 LeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgProAsnLeuGlu

N
 S
 i
 I

181 AGGCATTCAACAGGGCTGTCAAGAGTTTACAGAATGCATCAGCAATTGAGAGCATTCTTA
 -----+-----+-----+-----+-----+-----+ 240
 TCCGTAAGTTGTCCCGACAGTTCTCAAATGTCTTACGTAGTCGTTAACTCTCGTAAGAAT
 AlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlaIleGluSerIleLeuLys

241 AAAATCTCCTGCCATGTCTGCCCCTGGCCACGGCCGACCCACGCGACATCCAATCCATA
 -----+-----+-----+-----+-----+-----+ 300
 TTTTAGAGGACGGTACAGACGGGGACCGGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTAT
 AsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIle

FIG. 3A

E
C
O
R
I

301 TCAAGGACGGTGACTGGAATGAATTCCGTCGTAACTGACCTTCTATCTGAAAACCTTGG
-----+-----+-----+-----+-----+ 360
AGTTCCTGCCACTGACCTTACTTAAGGCAGCATTGACTGGAAGATAGACTTTTGAACC

LysAspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGlu

N h e I

H
i
n
d
I
I
I

361 AGAACGCGCAGGCTCAACAGACCACTCTGTCGCTAGCGATCTTTTAATAAGCTT
-----+-----+-----+-----+-----+ 414
TCTTGCGCGTCCGAGTTGTCTGGTGAGACAGCGATCGCTAGAAAATTATTCGAA

AsnAlaGlnAlaGlnGlnThrThrLeuSerLeuAlaIlePheEndEnd

FIG. 3B




FIG. 4




FIG. 5






FIG. 6





NCOI

lamB Signal Peptide

FIG. 8

**FIG. 9**





**Synthetic
Oligonucleotides**

EcoRI HindIII

**DNA sequence terminate
hIL-3 coding sequence
after codon 125**

Cleave with EcoRI and HindIII.

**Mix cleaved vector
with oligonucleotides.
Transform E. coli JM101
cells to ampicillin resistance.**





FIG. 11

5' CATGGCTAACTGCTCTAACATGAT 3'
SEQ ID NO:151

3' CGATTGACGAGATTGTACTAGC 5'
SEQ ID NO:152

Annealed
oligonucleotides



Ligated fragments

Transformed into
JM101




FIG. 12




FIG. 13




FIG. 14








FIG. 15

**FIG. 16**

**FIG. 17**

**FIG. 18**

**FIG. 19**




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24